Nonviolent action: How it works

https://stars.library.ucf.edu/prism/1325/thumbnail.jp

Direct Action: Protest and the Reinvention of American Radicalism by L.A. Kauffman

Book revie

Organics Substantially Reduce HO2 Uptake Onto Aerosols Containing Transition Metal ions

A HO2 mass accommodation coefficient of α = 0.23 ± 0.07 was measured onto sub-micron copper (II) doped ammonium sulphate aerosols at a relative humidity of 60 ± 3 %, at 293 ± 2 K and at an initial HO2 concentration of ~ 1 × 109 molecule cm-3 using an aerosol flow tube coupled to a sensitive Fluorescence Assay by Gas Expansion (FAGE) HO2 detection system. The effect upon the HO2 uptake coefficient γ of adding different organic species (malonic acid, citric acid, 1,2 diaminoethane, tartronic acid, ethylenediaminetetraacetic acid (EDTA) and oxalic acid) into the copper (II) doped aerosols was investigated. The HO2 uptake coefficient decreased steadily from the mass accommodation value to γ = 0.008 ± 0.009 when EDTA was added in a one-to-one molar ratio with the copper (II) ions, and to γ = 0.003 ± 0.004 when oxalic acid was added into the aerosol in a ten-to-one molar ratio with the copper (II). EDTA binds strongly to copper (II) ions potentially making them unavailable for catalytic destruction of HO2, and could also be acting as a surfactant or changing the viscosity of the aerosol. The addition of oxalic acid to the aerosol potentially forms low-volatility copper-oxalate complexes that reduce the uptake of HO2 either by changing the viscosity of the aerosol or causing precipitation out of the aerosol forming a coating. It is likely that there is a high enough oxalate to copper (II) ion ratio in many types of atmospheric aerosols to decrease the HO2 uptake coefficient. No observable change in the HO2 uptake coefficient was measured when the other organic species (malonic acid, citric acid, 1,2 diaminoethane and tartronic acid) were added in a ten-to-one molar ratio with the copper (II) ions

Hepatic effects of tartrazine (E 102) after systemic exposure are independent of oestrogen receptor interactions in the mouse

Tartrazine is a food colour that activates the transcriptional function of the human oestrogen receptor alpha in an in vitro cell model. Since oestrogens are cholestatic, we hypothesised tartrazine will cause periportal injury to the liver in vivo. To test this hypothesis, tartrazine was initially administered systemically to mice resulting in a periportal recruitment of inflammatory cells, increased serum alkaline phosphatase activity and mild periportal fibrosis. To determine whether an oestrogenic effect may be a key event in this response, tartrazine, sulphonated metabolites and a food additive contaminant were screened for their ability to interact with murine oestrogen receptors. In all cases, there were no interactions as agonists or antagonists and further, no oestrogenicity was observed with tartrazine in an in vivo uterine growth assay. To examine the relevance of the hepatic effects of tartrazine to its use as a food additive, tartrazine was orally administered to transgenic NF-κB-Luc mice. Pre- and concurrent oral treatment with alcohol was incorporated given its potential to promote gut permeability and hepatic inflammation. Tartrazine alone induced NF- κB activities in the colon and liver but there was no periportal recruitment of inflammatory cells or fibrosis. Tartrazine, its sulphonated metabolites and the contaminant inhibited sulphotransferase activities in murine hepatic S9 extracts. Given the role of sulfotransferases in bile acid excretion, the initiating event giving rise to periportal inflammation and subsequent hepatic pathology through systemic tartrazine exposure is therefore potentially associated an inhibition of bile acid sulphation and excretion and not on oestrogen receptor-mediated transcriptional function. However, these effects were restricted to systemic exposures to tartrazine and did not occur to any significant effect after oral exposure

The Uptake of HO₂ on Meteoric Smoke Analogues

The kinetics of heterogeneous HO2 uptake onto Meteoric Smoke Particles (MSPs) has been studied in the laboratory using analogues of MSP aerosol entrained into a flow tube. The uptake coefficient, y, was determined on synthetic amorphous olivine (MgFeSiO4) to be (6.9 ± 1.2) × 10‐2 at a relative humidity (RH) of 10%. On forsterite (Mg2SiO4), y = (4.3 ± 0.4) × 10‐3 at RH = 11.6%, and (7.3 ± 0.4) × 10‐2 at RH = 9.9% on fayalite (Fe2SiO4). These results indicate that Fe plays a more important mechanistic role than Mg in the removal of HO2 from the gas phase. Electronic structure calculations show that Fe atoms exposed at the particle surface provide a catalytic site where HO2 is converted to H2O2 via an Eley‐Rideal mechanism, but this does not occur on exposed surface Mg atoms. The impact of this heterogeneous process in the middle atmosphere was then investigated using a whole atmosphere chemistry‐climate model which incorporates a microphysical treatment of MSPs. Using a global MSP production rate from meteoric ablation of 44 tons per day, heterogeneous uptake (with y = 0.2) on MSPs significantly alters the HOx budget in the night‐time polar vortex. This impact is highly latitude dependent and thus could not be confirmed using currently available satellite measurements of HO2, which are largely unavailable at latitudes greater than 70°

Measuring the quality and quantity of professional intrapartum support: Testing a computerised systematic observation tool in the clinical setting

Background: Continuous support in labour has a significant impact on a range of clinical outcomes, though whether the quality and quantity of support behaviours affects the strength of this impact has not yet been established. To identify the quality and quantity of support, a reliable means of measurement is needed. To this end, a new computerised systematic observation tool, the ‘SMILI' (Supportive Midwifery in Labour Instrument) was developed. The aim of the study was to test the validity and usability of the ‘Supportive Midwifery in Labour Instrument' (SMILI) and to test the feasibility and acceptability of the systematic observation approach in the clinical intrapartum setting. Methods: Systematic observation was combined with a postnatal questionnaire and the collection of data about clinical processes and outcomes for each observed labour. The setting for the study was four National Health Service maternity units in Scotland, UK. Participants in this study were forty five midwives and forty four women. The SMILI was used by trained midwife observers to record labour care provided by midwives. Observations were undertaken for an average of two hours and seventeen minutes during the active first stage of labour and, in 18 cases, the observation included the second stage of labour. Content validity of the instrument was tested by the observers, noting the extent to which the SMILI facilitated the recording of all key aspects of labour care and interactions. Construct validity was tested through exploration of correlations between the data recorded and women's feelings about the support they received. Feasibility and usability data were recorded following each observation by the observer. Internal reliability and construct validity were tested through statistical analysis of the data. Results: One hundred and four hours of labour care were observed and recorded using the SMILI during forty nine labour episodes. Conclusion: The SMILI was found to be a valid and reliable instrument in the intrapartum setting in which it was tested. The study identified that the SMILI could be used to test correlations between the quantity and quality of support and outcomes. The systematic observational approach was found to be an acceptable and feasible method of enquiry

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

Abstract BACKGROUND: The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown. METHODS: We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, to receive subcutaneous injections of extended-release exenatide at a dose of 2 mg or matching placebo once weekly. The primary composite outcome was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The coprimary hypotheses were that exenatide, administered once weekly, would be noninferior to placebo with respect to safety and superior to placebo with respect to efficacy. RESULTS: In all, 14,752 patients (of whom 10,782 [73.1%] had previous cardiovascular disease) were followed for a median of 3.2 years (interquartile range, 2.2 to 4.4). A primary composite outcome event occurred in 839 of 7356 patients (11.4%; 3.7 events per 100 person-years) in the exenatide group and in 905 of 7396 patients (12.2%; 4.0 events per 100 person-years) in the placebo group (hazard ratio, 0.91; 95% confidence interval [CI], 0.83 to 1.00), with the intention-to-treat analysis indicating that exenatide, administered once weekly, was noninferior to placebo with respect to safety (P<0.001 for noninferiority) but was not superior to placebo with respect to efficacy (P=0.06 for superiority). The rates of death from cardiovascular causes, fatal or nonfatal myocardial infarction, fatal or nonfatal stroke, hospitalization for heart failure, and hospitalization for acute coronary syndrome, and the incidence of acute pancreatitis, pancreatic cancer, medullary thyroid carcinoma, and serious adverse events did not differ significantly between the two groups. CONCLUSIONS: Among patients with type 2 diabetes with or without previous cardiovascular disease, the incidence of major adverse cardiovascular events did not differ significantly between patients who received exenatide and those who received placebo. (Funded by Amylin Pharmaceuticals; EXSCEL ClinicalTrials.gov number, NCT01144338 .)